InGel Therapeutics

Allston, MA · Founded 2022 · Privately Held (backing)

Developer of engineered cell therapy designed to target neuroprotective pathways to treat retinal degeneration. InGel Therapeutics is based in Allston, MA and was founded in 2022. It was valued at $17 million at its seed round in Jul 2024, the last priced event on record. It has raised $10.8 million across 1 recorded round; the latest was a $350,000 seed round in Jul 2022.

PMV mark · valuation
$17.0M
Oct 2026
Priced at
its seed round
Jul 2024
Total raised
$10.8M
Last round
Seed Round
Jul 2022
What is InGel Therapeutics worth?
$17.0MPrivateMarketView mark · Oct 2026

Valued at $17.0M at its seed round, Jul 2024. Nothing has traded since.

Free account
More of InGel Therapeutics with a free account
  • ·The complete investor list: 16 names
  • ·Watch InGel Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

InGel Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Jul 2022Seed Round$350K▮
Unlock post-money valuations

Membership and data by Private Market View

InGel Therapeutics valuation

InGel Therapeutics was valued at $17 million at its seed round in Jul 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has InGel Therapeutics raised?

InGel Therapeutics has raised $10.8 million in total; 1 of its rounds is on record. The largest on record was a $350,000 seed round in Jul 2022.

InGel Therapeutics has filed 1 Form D with the SEC, most recently in Aug 2022 ($350,000 sold to 4 investors).

How InGel Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For InGel Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about InGel Therapeutics

What is InGel Therapeutics worth?
InGel Therapeutics is valued at $17.0M as of Oct 2026. Valued at $17.0M at its seed round, Jul 2024. Nothing has traded since.
How much has InGel Therapeutics raised?
InGel Therapeutics has raised $10.8M in total funding across 1 recorded rounds.
When did InGel Therapeutics last raise?
InGel Therapeutics last raised in Jul 2022 (Seed Round), raising $350K.